Abstract:AIM To evaluate the safety of lamivudine (LAM) treatment for chronic hepatitis B in early pregnancy. METHODS A total of 92 pregnant women who received LAM treatment either before pregnancy or in early pregnancy were enrolled in this study. All of the pregnant women volunteered to take lamivudine during pregnancy and were not co-infected with hepatitis C virus, human immunodeﬁciency virus, cytomegalovirus, or other viruses. All infants received passive-active immunoprophylaxis with 200 IU hepatitis B immunoglobulin and three doses of 10 μg hepatitis B vaccines (0-1-6 mo) according to the guidelines for the prevention and treatment of chronic hepatitis B. Adverse events were observed throughout the entire pregnancy and perinatal period, and the effectiveness of lamivudine treatment for blocking mother-to-infant transmission of hepatitis B virus (HBV) was evaluated. All adverse events in mothers and infants during pregnancy and the perinatal period and the HBV mother-to-infant transmission blocking rate were compared with the literature. RESULTS Among the 92 pregnant women, spontaneous abortions occurred in 11 cases, while 3 mothers had a second pregnancy after the initial abortion; 72 mothers delivered 73 live infants, of whom 68 infants were followed up for no less than 6 mo, and 12 mothers were still pregnant. During pregnancy, the main maternal adverse events were vaginitis (12/72, 16.7%), spontaneous abortion (11/95, 11.6%), and gestational diabetes (6/72, 8.3%); only one case had 1-2 degree elevation of the creatine kinase level (195 U/L). During the perinatal period, the main maternal adverse events were premature rupture of the membranes (8/72, 11.1%), preterm delivery (5/72, 6.9%), and meconium staining of the amniotic fluid (4/72, 5.6%). In addition, 2 infants were found to have congenital abnormalities; 1 had a scalp hemangioma that did not change in size until 7 mo, and the other had early cerebral palsy, but with rehabilitation training, the infant's motor functions became totally normal at 2 years of age. The incidence of adverse events among the mothers or abnormalities in the infants was not higher than that of normal mothers or HBV-infected mothers who did not receive lamivudine treatment. In only 2 cases, mother-to-infant transmission blocking failed; the blocking rate was 97.1% (66/68), which was higher than has been previously reported. CONCLUSION Lamivudine treatment is safe for chronic HBV-infected pregnant mothers and their fetuses with a gestational age of less than 12 wk or throughout the entire pregnancy.

Study on safety of telbivudine in treating hepatitis B virus infection in pregnant transgenic mice

Study on Safety of Telbivudine in Treatment of Hepatitis B Virus Transgenic Mice with Pregnancy and Efficacy of Preventing HBV Mother-to-Child

Safety of Anti-hepatitis B Virus Therapy During Pregnancy and Lactation

Effect of Prophylactic Antiviral Intervention on T Cell Immunity in Hepatitis B Virus-Infected Pregnant Women

Evaluation of the Efficacy and Safety of Telbivudin in Preventing Mother-to-infant HBV Transmission

Prospective Cohort Study on the Efficacy and Safety of Telbivudine Used Throughout Pregnancy in Blocking Mother-to-child Transmission of Hepatitis B Virus.

Safety and Efficacy of Telbivudine in Late Pregnancy to Prevent Mother‐to‐child Transmission of Hepatitis B Virus: A Multicenter Prospective Cohort Study

Telbivudine Can Safely Reduce Mother-to-child Transmission in Chronic Hepatitis B Women after 12 Weeks of Gestation

Effect of withdrawal time on postpartum liver function in pregnant women receiving tenofovir disoproxil fumarate therapy for blocking mother to child transmission of hepatitis B

Safety of Telbivudine Treatment for Chronic Hepatitis B for the Entire Pregnancy

Comparison of telbivudine versus lamivudine in interrupting perinatal transmission of hepatitis B virus

Telbivudine during the second and third trimester of pregnancy interrupts HBV intrauterine transmission: a systematic review and meta-analysis.

High prevalence of pre-existing HBV polymerase mutations in pregnant women do not limit the telbivudine treatment efficacy

Analysis of long-term safety and efficacy of nucleos(t)ide analogue therapy for chronic hepatitis B throughout pregnancy

Efficacy and Safety of Telbivudine and Tenofovir Disoproxil Fumarate in Preventing Hepatitis B Vertical Transmission: A Real‐life Practice

Safety of Lamivudine Treatment for Chronic Hepatitis B in Early Pregnancy

Safety and Efficacy of Lamivudine or Telbivudine Started in Early Pregnancy for Mothers with Active Chronic Hepatitis B

Efficacy and Safety of Lamivudine Treatment for Chronic Hepatitis B in Pregnancy

Lamivudine vs placebo or no treatment in preventing the transmission of hepatitis B virus during pregnancy: a systematic review and meta-analysis

Telbivudine Therapy for Gravidas with Chronic Hepatitis B Infection and Patients at Risk of Renal Impairment

Comparison of HBV-DNA and HBeAg As Antiviral Therapeutic Indicators among HBV-infected Pregnant Women: a Systematic Review and Meta-Analysis